Abstract
Toxoplasma gondii is a ubiquitous pathogen that causes significant morbidity and mortality in immunocompromised patients. Although relatively uncommon, toxoplasmosis is increasingly recognized as a severe complication of hematopoietic stem cell transplantation. Timely and accurate diagnosis of this treatable infection is critical. PCR-based testing has become the preferred method for diagnosis, occasionally replacing tissue biopsy. This article reviews the clinical, diagnostic and therapeutic aspects of toxoplasmosis in the setting of hematopoietic stem cell transplantation and the current and future role of PCR-based testing for early detection and diagnosis.
MeSH terms
-
Animals
-
Antibodies, Protozoan / blood
-
Antibodies, Protozoan / immunology
-
Antiprotozoal Agents / therapeutic use
-
Computer Systems
-
DNA, Protozoan / analysis
-
Forecasting
-
Humans
-
Immunocompromised Host
-
Mass Screening / economics
-
Peripheral Blood Stem Cell Transplantation*
-
Polymerase Chain Reaction / methods*
-
Premedication
-
Sensitivity and Specificity
-
Seroepidemiologic Studies
-
Toxoplasma / genetics
-
Toxoplasma / immunology
-
Toxoplasmosis / diagnosis*
-
Toxoplasmosis / economics
-
Toxoplasmosis / epidemiology
-
Toxoplasmosis / prevention & control
-
Toxoplasmosis, Cerebral / diagnosis
-
Toxoplasmosis, Cerebral / epidemiology
-
Toxoplasmosis, Cerebral / prevention & control
-
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
Substances
-
Antibodies, Protozoan
-
Antiprotozoal Agents
-
DNA, Protozoan
-
Trimethoprim, Sulfamethoxazole Drug Combination